• About Us
    • Company Overview
    • Our History
    • Leadership
    • Board of Directors
    • Our Advisors
  • Therapeutic Areas
    • COVID-19 and CVD
    • Acute Myocarditis
    • Heart Failure
  • Research
    • R&D Partners
    • Our Science
    • Resources
  • Pipeline
  • CardiolRX™
  • Investors
    • Events & Presentations
    • Press Releases
    • Analyst Coverage
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • Contact Us
News

Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference

September 15, 2020

Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx™

August 26, 2020

Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor

June 29, 2020

David Elsley Files Early Warning Report for Cardiol Therapeutics

June 25, 2020

Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option

June 04, 2020

Cardiol Therapeutics Reports 2020 AGM Results

June 02, 2020

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 1st at 4:30 p.m. EDT

May 29, 2020

Cardiol Therapeutics Announces Increase to Previously Announced Bought Deal Public Offering

May 14, 2020

Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering

May 13, 2020

Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19

May 06, 2020
Page 2 of 7«12345...»Last »
  • About Us
  • Therapeutic Areas
  • Research
  • Pipeline
  • CardiolRX™
  • Investors
  • Contact

TSX:CRDL OTCQX:CRTPF FSE:CT9

Sign up to receive the latest news from Cardiol Therapeutics

© 2021 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy